Clinical trial
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With…
NCT00126451 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00126451 |
|---|---|
| Title | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED) |
| Official title | A Phase II Clinical Study of Oral Suberoylanilide Hydroxamic Acid in Patients With Relapsed or Refractory Breast, Colorectal, and Non-small Cell Lung Cancer. |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Colorectal Cancer, Non-small-cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA), Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles |
| Enrollment | 16 |
| Start date | Dec 1, 2004 |
| Primary completion | Oct 11, 2005 |
| Completion | Oct 11, 2005 |
| First posted | Aug 4, 2005 |
| Last update posted | Apr 10, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: